Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUVOLA Trial: Neoadjuvant Olaparib + Weekly Carboplatin/Paclitaxel in Unresectable Ovarian Cancer
2018-002687-65Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib, carboplatin and paclitaxel in High-Grade Serous Ovarian Cancer (HGSOC) and Serous Papillary Cystadenocarcinoma, sponsored by Policlinico Gemelli. Primary endpoint: Pathological complete response. Started May 2021; status: completed.
02
Drugs
olaparibcarboplatinpaclitaxel
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on 2018-002687-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002687-65.